PMC:7200337 / 99901-100787 JSONTXT

{"project":"2_test","denotations":[{"id":"32505227-16940336-46575435","span":{"begin":589,"end":593},"obj":"16940336"},{"id":"32505227-21248066-46575436","span":{"begin":625,"end":629},"obj":"21248066"},{"id":"32505227-27405596-46575437","span":{"begin":662,"end":666},"obj":"27405596"},{"id":"T69935","span":{"begin":589,"end":593},"obj":"16940336"},{"id":"T78315","span":{"begin":625,"end":629},"obj":"21248066"},{"id":"T33973","span":{"begin":662,"end":666},"obj":"27405596"}],"text":"Although recombinant nAbs could provide an effective treatment, they will require a significant time investment to develop, test, and bring production to scale before becoming widely available to patients. A faster strategy consists of transferring convalescent plasma (CP) from previously infected individuals that have developed high titer nAbs that target SARS-CoV-2 (Figure 6D). Despite the current lack of appropriately controlled trials, CP therapy has been previously used and shown to be beneficial in several infectious diseases, such as the 1918 influenza pandemic (Luke et al., 2006), H1N1 influenza (Hung et al., 2011), and SARS-CoV-1 (Arabi et al., 2016). Thanks to the development of serological tests (Amanat et al., 2020, Cai et al., 2020, Xiang et al., 2020b, Zhang et al., 2020d), recovered COVID-19 patients can be screened to select plasma with high antibody titers."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":262,"end":268},"obj":"Body_part"},{"id":"T2","span":{"begin":853,"end":859},"obj":"Body_part"},{"id":"T3","span":{"begin":870,"end":878},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"Although recombinant nAbs could provide an effective treatment, they will require a significant time investment to develop, test, and bring production to scale before becoming widely available to patients. A faster strategy consists of transferring convalescent plasma (CP) from previously infected individuals that have developed high titer nAbs that target SARS-CoV-2 (Figure 6D). Despite the current lack of appropriately controlled trials, CP therapy has been previously used and shown to be beneficial in several infectious diseases, such as the 1918 influenza pandemic (Luke et al., 2006), H1N1 influenza (Hung et al., 2011), and SARS-CoV-1 (Arabi et al., 2016). Thanks to the development of serological tests (Amanat et al., 2020, Cai et al., 2020, Xiang et al., 2020b, Zhang et al., 2020d), recovered COVID-19 patients can be screened to select plasma with high antibody titers."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T99","span":{"begin":154,"end":159},"obj":"Body_part"}],"attributes":[{"id":"A99","pred":"uberon_id","subj":"T99","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"}],"text":"Although recombinant nAbs could provide an effective treatment, they will require a significant time investment to develop, test, and bring production to scale before becoming widely available to patients. A faster strategy consists of transferring convalescent plasma (CP) from previously infected individuals that have developed high titer nAbs that target SARS-CoV-2 (Figure 6D). Despite the current lack of appropriately controlled trials, CP therapy has been previously used and shown to be beneficial in several infectious diseases, such as the 1918 influenza pandemic (Luke et al., 2006), H1N1 influenza (Hung et al., 2011), and SARS-CoV-1 (Arabi et al., 2016). Thanks to the development of serological tests (Amanat et al., 2020, Cai et al., 2020, Xiang et al., 2020b, Zhang et al., 2020d), recovered COVID-19 patients can be screened to select plasma with high antibody titers."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T576","span":{"begin":359,"end":367},"obj":"Disease"},{"id":"T577","span":{"begin":518,"end":528},"obj":"Disease"},{"id":"T578","span":{"begin":556,"end":565},"obj":"Disease"},{"id":"T579","span":{"begin":596,"end":610},"obj":"Disease"},{"id":"T580","span":{"begin":601,"end":610},"obj":"Disease"},{"id":"T581","span":{"begin":636,"end":644},"obj":"Disease"},{"id":"T582","span":{"begin":809,"end":817},"obj":"Disease"}],"attributes":[{"id":"A576","pred":"mondo_id","subj":"T576","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A577","pred":"mondo_id","subj":"T577","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A578","pred":"mondo_id","subj":"T578","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A579","pred":"mondo_id","subj":"T579","obj":"http://purl.obolibrary.org/obo/MONDO_0005460"},{"id":"A580","pred":"mondo_id","subj":"T580","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A581","pred":"mondo_id","subj":"T581","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A582","pred":"mondo_id","subj":"T582","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Although recombinant nAbs could provide an effective treatment, they will require a significant time investment to develop, test, and bring production to scale before becoming widely available to patients. A faster strategy consists of transferring convalescent plasma (CP) from previously infected individuals that have developed high titer nAbs that target SARS-CoV-2 (Figure 6D). Despite the current lack of appropriately controlled trials, CP therapy has been previously used and shown to be beneficial in several infectious diseases, such as the 1918 influenza pandemic (Luke et al., 2006), H1N1 influenza (Hung et al., 2011), and SARS-CoV-1 (Arabi et al., 2016). Thanks to the development of serological tests (Amanat et al., 2020, Cai et al., 2020, Xiang et al., 2020b, Zhang et al., 2020d), recovered COVID-19 patients can be screened to select plasma with high antibody titers."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":82,"end":83},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T2","span":{"begin":124,"end":128},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T3","span":{"begin":206,"end":207},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T4","span":{"begin":262,"end":268},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T5","span":{"begin":270,"end":272},"obj":"http://purl.obolibrary.org/obo/PR_000005794"},{"id":"T6","span":{"begin":444,"end":446},"obj":"http://purl.obolibrary.org/obo/PR_000005794"},{"id":"T7","span":{"begin":455,"end":458},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T8","span":{"begin":710,"end":715},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T9","span":{"begin":853,"end":859},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"}],"text":"Although recombinant nAbs could provide an effective treatment, they will require a significant time investment to develop, test, and bring production to scale before becoming widely available to patients. A faster strategy consists of transferring convalescent plasma (CP) from previously infected individuals that have developed high titer nAbs that target SARS-CoV-2 (Figure 6D). Despite the current lack of appropriately controlled trials, CP therapy has been previously used and shown to be beneficial in several infectious diseases, such as the 1918 influenza pandemic (Luke et al., 2006), H1N1 influenza (Hung et al., 2011), and SARS-CoV-1 (Arabi et al., 2016). Thanks to the development of serological tests (Amanat et al., 2020, Cai et al., 2020, Xiang et al., 2020b, Zhang et al., 2020d), recovered COVID-19 patients can be screened to select plasma with high antibody titers."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T12461","span":{"begin":270,"end":272},"obj":"Chemical"},{"id":"T92128","span":{"begin":444,"end":446},"obj":"Chemical"}],"attributes":[{"id":"A97343","pred":"chebi_id","subj":"T12461","obj":"http://purl.obolibrary.org/obo/CHEBI_3380"},{"id":"A43877","pred":"chebi_id","subj":"T12461","obj":"http://purl.obolibrary.org/obo/CHEBI_73461"},{"id":"A88951","pred":"chebi_id","subj":"T92128","obj":"http://purl.obolibrary.org/obo/CHEBI_3380"},{"id":"A32474","pred":"chebi_id","subj":"T92128","obj":"http://purl.obolibrary.org/obo/CHEBI_73461"}],"text":"Although recombinant nAbs could provide an effective treatment, they will require a significant time investment to develop, test, and bring production to scale before becoming widely available to patients. A faster strategy consists of transferring convalescent plasma (CP) from previously infected individuals that have developed high titer nAbs that target SARS-CoV-2 (Figure 6D). Despite the current lack of appropriately controlled trials, CP therapy has been previously used and shown to be beneficial in several infectious diseases, such as the 1918 influenza pandemic (Luke et al., 2006), H1N1 influenza (Hung et al., 2011), and SARS-CoV-1 (Arabi et al., 2016). Thanks to the development of serological tests (Amanat et al., 2020, Cai et al., 2020, Xiang et al., 2020b, Zhang et al., 2020d), recovered COVID-19 patients can be screened to select plasma with high antibody titers."}

{"project":"LitCovid-PubTator","denotations":[{"id":"3323","span":{"begin":444,"end":446},"obj":"Gene"},{"id":"3324","span":{"begin":270,"end":272},"obj":"Gene"},{"id":"3325","span":{"begin":843,"end":845},"obj":"Gene"},{"id":"3326","span":{"begin":676,"end":678},"obj":"Gene"},{"id":"3327","span":{"begin":490,"end":492},"obj":"Gene"},{"id":"3328","span":{"begin":193,"end":195},"obj":"Gene"},{"id":"3329","span":{"begin":151,"end":153},"obj":"Gene"},{"id":"3330","span":{"begin":112,"end":114},"obj":"Gene"},{"id":"3331","span":{"begin":196,"end":204},"obj":"Species"},{"id":"3332","span":{"begin":359,"end":369},"obj":"Species"},{"id":"3335","span":{"begin":818,"end":826},"obj":"Species"},{"id":"3336","span":{"begin":9,"end":20},"obj":"Species"},{"id":"3337","span":{"begin":556,"end":565},"obj":"Species"},{"id":"3339","span":{"begin":21,"end":25},"obj":"Chemical"},{"id":"3340","span":{"begin":342,"end":346},"obj":"Chemical"},{"id":"3341","span":{"begin":290,"end":298},"obj":"Disease"},{"id":"3342","span":{"begin":518,"end":537},"obj":"Disease"},{"id":"3343","span":{"begin":809,"end":817},"obj":"Disease"}],"attributes":[{"id":"A3323","pred":"tao:has_database_id","subj":"3323","obj":"Gene:1356"},{"id":"A3324","pred":"tao:has_database_id","subj":"3324","obj":"Gene:1356"},{"id":"A3325","pred":"tao:has_database_id","subj":"3325","obj":"Gene:6999"},{"id":"A3326","pred":"tao:has_database_id","subj":"3326","obj":"Gene:6999"},{"id":"A3327","pred":"tao:has_database_id","subj":"3327","obj":"Gene:6999"},{"id":"A3328","pred":"tao:has_database_id","subj":"3328","obj":"Gene:6999"},{"id":"A3329","pred":"tao:has_database_id","subj":"3329","obj":"Gene:6999"},{"id":"A3330","pred":"tao:has_database_id","subj":"3330","obj":"Gene:6999"},{"id":"A3331","pred":"tao:has_database_id","subj":"3331","obj":"Tax:9606"},{"id":"A3332","pred":"tao:has_database_id","subj":"3332","obj":"Tax:2697049"},{"id":"A3335","pred":"tao:has_database_id","subj":"3335","obj":"Tax:9606"},{"id":"A3336","pred":"tao:has_database_id","subj":"3336","obj":"Tax:575864"},{"id":"A3337","pred":"tao:has_database_id","subj":"3337","obj":"Tax:11520"},{"id":"A3341","pred":"tao:has_database_id","subj":"3341","obj":"MESH:D007239"},{"id":"A3342","pred":"tao:has_database_id","subj":"3342","obj":"MESH:D003141"},{"id":"A3343","pred":"tao:has_database_id","subj":"3343","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Although recombinant nAbs could provide an effective treatment, they will require a significant time investment to develop, test, and bring production to scale before becoming widely available to patients. A faster strategy consists of transferring convalescent plasma (CP) from previously infected individuals that have developed high titer nAbs that target SARS-CoV-2 (Figure 6D). Despite the current lack of appropriately controlled trials, CP therapy has been previously used and shown to be beneficial in several infectious diseases, such as the 1918 influenza pandemic (Luke et al., 2006), H1N1 influenza (Hung et al., 2011), and SARS-CoV-1 (Arabi et al., 2016). Thanks to the development of serological tests (Amanat et al., 2020, Cai et al., 2020, Xiang et al., 2020b, Zhang et al., 2020d), recovered COVID-19 patients can be screened to select plasma with high antibody titers."}

{"project":"LitCovid-sentences","denotations":[{"id":"T586","span":{"begin":0,"end":205},"obj":"Sentence"},{"id":"T587","span":{"begin":206,"end":382},"obj":"Sentence"},{"id":"T588","span":{"begin":383,"end":668},"obj":"Sentence"},{"id":"T589","span":{"begin":669,"end":886},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Although recombinant nAbs could provide an effective treatment, they will require a significant time investment to develop, test, and bring production to scale before becoming widely available to patients. A faster strategy consists of transferring convalescent plasma (CP) from previously infected individuals that have developed high titer nAbs that target SARS-CoV-2 (Figure 6D). Despite the current lack of appropriately controlled trials, CP therapy has been previously used and shown to be beneficial in several infectious diseases, such as the 1918 influenza pandemic (Luke et al., 2006), H1N1 influenza (Hung et al., 2011), and SARS-CoV-1 (Arabi et al., 2016). Thanks to the development of serological tests (Amanat et al., 2020, Cai et al., 2020, Xiang et al., 2020b, Zhang et al., 2020d), recovered COVID-19 patients can be screened to select plasma with high antibody titers."}